Sagimet Biosciences (SGMT) Preferred Stock Liabilities (2023)
Sagimet Biosciences has reported Preferred Stock Liabilities over the past 1 years, most recently at $214.6 million for Q2 2023.
Sagimet Biosciences has reported Preferred Stock Liabilities over the past 1 years, most recently at $214.6 million for Q2 2023.